Crestor and Oncovin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Crestor (rosuvastatin calcium) and Oncovin (vincristine sulfate). Common drug interactions include hypokalaemia among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Crestor and Oncovin. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Crestor?

Crestor has active ingredients of rosuvastatin calcium. It is often used in high blood cholesterol. eHealthMe is studying from 149,762 Crestor users. Check the latest studies of Crestor.

What is Oncovin?

Oncovin has active ingredients of vincristine sulfate. eHealthMe is studying from 6,667 Oncovin users. Check the latest studies of Oncovin.

On Aug, 07, 2026

12 people who take Crestor and Oncovin together, and have interactions are studied.

What are the common drug interactions of Crestor and Oncovin, by gender? *:

female:

Hypokalaemia (low potassium)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Inappropriate antidiuretic hormone secretion
Lymphocytic leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes)
C-reactive protein increased
Leukocytosis (increased white blood cells)
Migraine (headache)
Platelet count increased
Pyrexia (fever)

male:

Dyspnoea (difficult or laboured respiration)
Lung neoplasm malignant (cancer tumour of lung)
B-cell lymphoma recurrent (blood cancer affecting b cells-recurrent)
Blood pressure inadequately controlled
Burning sensation
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Pneumonia bacterial (pneumonia associated with bacterial infection)
B-cell lymphoma (blood cancer affecting b cells)
Blood pressure systolic decreased
Decreased appetite

What are the common drug interactions of Crestor and Oncovin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Interstitial lung disease

50-59:

Blood pressure systolic decreased
Decreased appetite
Dehydration (dryness resulting from the removal of water)
Fatigue (feeling of tiredness)
Nasopharyngitis (inflammation of the nasopharynx)
Recurrent cancer (repeated cancer)

60+:

Dyspnoea (difficult or laboured respiration)
Hypokalaemia (low potassium)
Gait disturbance
Metastases to meninges (cancer spreads to meninges)
Cerebral infarction (less blood supply to brain resulting tissue damage)
Platelet count decreased
B-cell lymphoma recurrent (blood cancer affecting b cells-recurrent)
Blood pressure inadequately controlled
Burning sensation
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 4 people, 33.33%
High Blood Pressure: 2 people, 16.67%
Lymphoma (cancer that begins in immune system cells): 2 people, 16.67%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 16.67%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 16.67%
Constipation: 2 people, 16.67%
Gastric Cancer (stomach cancer): 2 people, 16.67%
Gastric Ulcer (stomach ulcer): 2 people, 16.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 16.67%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Crestor and Oncovin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously